GlassScriptPhysician profile
Ronald C Marts
NPI 1114027299
$1,670.48
in general payments reported to CMS, 2019-2025
27 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $96.38 · 2021: $223 · 2022: $373 · 2023: $496 · 2024: $175 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $867.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $200.56 | 2022-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $170.56 | 2021-2024 | Caplyta |
| Pfizer INC. | $136.78 | 2019-2023 | |
| Ironshore Pharmaceuticals INC. | $131.41 | 2021-2024 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $123.81 | 2021-2023 | Rexulti, Abilify Maintena |
| Abbvie INC. | $116.87 | 2021-2024 | |
| Vanda Pharmaceuticals INC. | $113.39 | 2021-2023 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $102.66 | 2019-2022 | |
| Exact Sciences Corporation | $77.02 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $70.45 | 2022-2025 | Mounjaro, Zepbound |
| Amgen INC. | $66.34 | 2019-2020 | |
| Corium, LLC | $39.10 | 2022 | |
| Novo Nordisk INC | $35.45 | 2021-2025 | Ozempic |
| Gilead Sciences, INC. | $34.47 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $32.14 | 2022-2025 | Austedo Xr |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $28.70 | 2025 | |
| Ardelyx, INC. | $27.47 | 2025 | Ibsrela |
| Abbott Laboratories | $24.72 | 2025 | Freestyle Libre |
| Dexcom, INC. | $23.40 | 2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $18.03 | 2024 | Veozah |
| Axsome Therapeutics, INC. | $15.27 | 2024 | Auvelity |
| Lundbeck LLC | $15.13 | 2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $14.02 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.86 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $13.59 | 2023 | Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.58 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Marts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.